干旱区生态环境知识资源中心(Arid): Omadacycline for Acute Bacterial Skin and Skin Structure Infections

Arid

DOI	10.1093/cid/ciz396
	Omadacycline for Acute Bacterial Skin and Skin Structure Infections
	Abrahamian, Fredrick M.1,2; Sakoulas, George 3; Tzanis, Evan 4; Manley, Amy 4; Steenbergen, Judith 4; Das, Anita F.5; Eckburg, Paul B.4; McGovern, Paul C.4
通讯作者	McGovern, Paul C.
来源期刊	CLINICAL INFECTIOUS DISEASES
ISSN	1058-4838
EISSN	1537-6591
出版年	2019
卷号	69 页码:S23-S32
英文摘要	Background. Within the last decade, methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a frequent cause of purulent skin and soft tissue infections. New therapeutic options are being investigated for these infections. Methods. We report an integrated analysis of 2 randomized, controlled studies involving omadacycline, a novel aminomethylcycline, and linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Omadacycline in Acute Skin and Skin Structure Infections Study 1 (OASIS-1) initiated patients on intravenous omadacycline or linezolid, with the option to transition to an oral formulation after day 3. OASIS-2 was an oral-only study of omadacycline versus linezolid. Results. In total, 691 patients received omadacycline and 689 patients received linezolid. Infection types included wound infection in 46.8% of patients, cellulitis/erysipelas in 30.5%, and major abscess in 22.7%. Pathogens were identified in 73.2% of patients. S. aureus was detected in 74.7% and MRSA in 32.4% of patients in whom a pathogen was identified. Omadacycline was noninferior to linezolid using the Food and Drug Administration primary endpoint of early clinical response (86.2% vs 83.9%; difference 2.3, 95% confidence interval -1.5 to 6.2) and using the European Medicines Agency primary endpoint of investigator-assessed clinical response at the posttreatment evaluation. Clinical responses were similar across different infection types and infections caused by different pathogens. Treatment-emergent adverse events, mostly described as mild or moderate, were reported by 51.1% of patients receiving omadacycline and 41.2% of those receiving linezolid. Conclusions. Omadacycline was effective and safe in ABSSSI.
英文关键词	omadacycline skin infection acute bacterial skin and skin structure infections tetracyclines MRSA
类型	Article
语种	英语
国家	USA
开放获取类型	hybrid, Green Published, Green Submitted
收录类别	SCI-E
WOS记录号	WOS:000485171400004
WOS关键词	SOFT-TISSUE INFECTIONS ; PRACTICE GUIDELINES ; MANAGEMENT ; EPIDEMIOLOGY ; TRANSITIONS ; CARE
WOS类目	Immunology ; Infectious Diseases ; Microbiology
WOS研究方向	Immunology ; Infectious Diseases ; Microbiology
来源机构	University of California, Los Angeles
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/214932
作者单位	1.Olive View UCLA Med Ctr, Dept Emergency Med, 14445 Olive View Dr, Sylmar, CA 91342 USA; 2.Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; 3.Univ Calif San Diego, Sch Med, Ctr Immun Infect & Inflammat, Div Host Microbe Syst & Therapeut, La Jolla, CA 92093 USA; 4.Paratek Pharmaceut Inc, 1000 1st Ave, King Of Prussia, PA 19406 USA; 5.AD Stats Consulting, Guerneville, CA USA
推荐引用方式 GB/T 7714	Abrahamian, Fredrick M.,Sakoulas, George,Tzanis, Evan,et al. Omadacycline for Acute Bacterial Skin and Skin Structure Infections[J]. University of California, Los Angeles,2019,69:S23-S32.
APA	Abrahamian, Fredrick M..,Sakoulas, George.,Tzanis, Evan.,Manley, Amy.,Steenbergen, Judith.,...&McGovern, Paul C..(2019).Omadacycline for Acute Bacterial Skin and Skin Structure Infections.CLINICAL INFECTIOUS DISEASES,69,S23-S32.
MLA	Abrahamian, Fredrick M.,et al."Omadacycline for Acute Bacterial Skin and Skin Structure Infections".CLINICAL INFECTIOUS DISEASES 69(2019):S23-S32.